

EDITORIAL

COVID-19 and multisystem inflammatory syndrome, or is it mast cell activation syndrome?T.C. Theoharides^{1,2,3} and P. Conti⁴

¹Laboratory of Molecular Immunopharmacology and Drug Discovery, Department of Immunology, Tufts University School of Medicine, Boston, MA, USA; ²School of Graduate Biomedical Sciences, Tufts University School of Medicine, Boston, MA, USA; ³Department of Internal Medicine, Tufts University School of Medicine and Tufts Medical Center, Boston, MA, USA; ⁴Postgraduate Medical School, University of Chieti, Chieti Italy

Received October 1, 2020 - Accepted October 7, 2020

COVID-19 derives from infection with Coronavirus [severe acute respiratory syndrome (SARS)-CoV-2] and is associated with high morbidity and mortality due to release of a storm of pro-inflammatory cytokines and thrombogenic agents resulting in destruction of the lungs. Many reports indicate that a considerable number of patients who are positive for SARS-CoV-2 are asymptomatic or have mild symptoms. However, increasing evidence suggests that many such patients who either recovered from or had mild symptoms after COVID-19 exhibit diffuse, multiorgan, symptoms months after the infection. These symptoms include malaise, myalgias, chest tightness, brain fog and other neuropsychiatric symptoms that were originally reported in children and named Multisystem Inflammatory Syndrome (MIS-C). Now the US Center for Disease Control (CDC) has announced the recognition of a similar condition in adults, named Multisystem Inflammatory Syndrome (MIS-A). The symptoms characterizing these conditions are very similar to those associated with Mast Cell Activation Syndrome (MCAS, US ICD-110 code D89.42-idiopathic mast cell activation syndrome). Hence, the possibility of MCAS should be evaluated in any patient with MIS and/or multisystem inflammatory symptoms. In either case, these syndromes should be addressed with liposomal formulation (in olive pomace oil) of the flavone luteolin (e.g. PureLut[®] or FibroProtek[®]) together with the antihistamine rupatadine, which also has anti-platelet activating factor (PAF) activity and inhibits mast cells that have been implicated in the pathogenesis of cytokine storms in COVID-19.

The recent Coronavirus [severe acute respiratory syndrome (SARS)-CoV-2] is associated with a high morbidity and mortality in adults, known as COVID-19 (1). Infected patients who recover have increased levels of specific antibodies and activated T cells (2, 3), but dysfunctional immune system (4). In particular, the pulmonary pathology results from release of multiple pro-inflammatory cytokines, especially IL-6 (2, 5), but also microthromboses that may involve platelet activating factor (PAF) (6).

Children and adolescents do get sick with COVID-19 (7), but generally present with milder symptoms than adults (8, 9). Nevertheless, a number of papers have reported the presence in children of Multisystem Inflammatory Syndrome (MIS-C) with symptoms resembling toxic shock or Kawasaki syndrome (10, 11). Symptoms in children were mostly nonspecific and included rash (52%), diarrhea (52%), vomiting (45%) and conjunctival injection (45%) with all children having increased indexes of inflammation (12).

Key words: multisystem inflammatory syndrome; MIS-C; MIS-A; COVID-19; SARS-CoV-2; inflammation; mast-cell; immunity; cytokine storm

Corresponding Author:

Theoharis C. Theoharides, MS, MPhil, PhD, MD
Department of Immunology, Tufts University School of Medicine,
136 Harrison Avenue, Suite 304,
Boston, MA 02111, USA
Tel.: +1 617 636 6866 - Fax: +1 617 636 2456
e-mail: theoharis.theoharides@tufts.edu

There has been increased realization that COVID-19 is associated with many extrapulmonary manifestations, including thrombotic complications, arrhythmias, gastrointestinal symptoms, as well as dermatologic and neurologic complications (12). In fact, the Centers for Disease Control (CDC) recently recognized the existence of a similar syndrome in adults, (<https://www.cdc.gov/mis-c/>) named Multisystem Inflammatory Syndrome (MIS-A). The symptoms characterizing this syndrome are numerous and affect almost all organs, including cardiovascular, gastrointestinal, dermatologic and neurologic symptoms, especially brain fog (Table I) (13, 14). Prominent among the neurologic manifestations is brain fog associated with confusion, inability to focus, loss of memory, and inability to find the right words that has been termed “COVID Brain Fog” (<https://www.nytimes.com/2020/10/11/health/covid-survivors.html>). MIS-A symptoms typically appear weeks to months after infection, giving the term “longhaulers” to such patients, and are worsened by psychological stress (15, 16). MIS-A symptoms and their worsening by stress are very similar to those (Table II) experienced by patients with mastocytosis (17) or mast cell activation syndrome (MCAS) (18). A unique aspect of MCAS is that the mast cells in these patients are stimulated by numerous non-allergic triggers, including stress-related peptides (19) without the release of histamine or tryptase (20).

A key source of pro-inflammatory cytokines in COVID-19 (21) is the mast cells (17, 22), which can be triggered by viruses (23), including SARS-CoV-2 (24), and secrete multiple pro-inflammatory mediators (25, 26), including IL-6 (27) and IL-1 β

(28), thus potentially contributing to COVID-19 pathology (24). Mast cells are ubiquitous in the body, located perivascularly, especially in the lungs where they mature under the influence of local micro-environmental factors resulting in different phenotypes. Mast cells are typically stimulated by allergens crosslinking allergen-specific immunoglobulin E (IgE) bound to high affinity Fc epsilon receptor 1 (Fc ϵ RI) (17), but also by non-IgE stimuli (29) such as cationic compounds via activation of the low affinity G-coupled receptor MRGPRX2 (30), as well as neuropeptides, including corticotropin-releasing hormone (CRH), neurotensin (NT), and substance P (SP) via high affinity receptors (31).

Following stimulation, mast cells rapidly secrete the preformed, granule-stored, heparin, histamine, tryptase and TNF, as well as newly synthesized leukotrienes, PAF, prostaglandin D₂ (PGD₂), cytokines (IL-5, IL-6, IL-31, IL-33 and TNF) and chemokines (CCL2, CCL5 and CXCL8) released 6-24 hours later (25). Some of these “late phase” mediators can be released without degranulation (19), as we showed for IL-6 (27) and IL-1 β (28). Mast cell-derived vasoactive mediators, especially cytokines (32), can also increase the permeability of the blood-brain barrier (BBB) (33). Hence, SARS-CoV-2 could lead to “COVID Brain Fog” either directly via activation of mast cells or by permitting cytokines to enter through a disrupted BBB.

Inhibition of mast cell-associated inflammation is necessary (34) and could be accomplished with some naturally occurring flavonoids, especially luteolin (23), which inhibits release of pro-inflammatory molecules

Table I. Working criteria for MIS-A

1. Severe illness requiring hospitalization in a person >21 years old
2. Positive test result for SARS-CoV-2 infection (current or within past 12 weeks)
3. Severe dysfunction of one or more extrapulmonary organ systems
4. Laboratory evidence of severe inflammation
5. Absence of severe respiratory illness

Table II. *Common symptoms present in MIS-A and MCAS*

- Angioedema
- Arrhythmias
- Brain fog
- Confusion
- Diarrhea
- Dizziness
- Dysautonomia
- Fatigue
- Gastrointestinal complaints
- Headache
- Hives
- Hypotension
- Lightheadedness (syncope)
- Inability to find the right word
- Memory loss
- Myalgias
- Palpitations
- Shortness of breath
- Skin rashes
- Weakness

from mast cells and also has anti-viral properties (24). Due to the poor solubility and oral absorption of luteolin, preferable formulations would be those using liposomal luteolin (e.g. FibroProtek®, BrainGain®) (35).

The presence of diffuse, multisystem inflammatory symptoms, especially “COVID Brain Fog” may be indicative of MCAS (24). Hence, in addition to the inflammatory markers discussed, it would be important to investigate mast cell-associated mediators and attempt to inhibit their release and/or their biological actions.

ACKNOWLEDGEMENTS

This work was supported by anonymous donations.

REFERENCES

1. Poon LLM, Peiris M. Emergence of a novel human coronavirus threatening human health. *Nat Med* 2020; 26(3):317-19.
2. Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. *J Clin Invest* 2020; 130(5):2620-29.
3. Thevarajan I, Nguyen THO, Koutsakos M et al. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. *Nat Med* 2020; 26(4):453-55.
4. Giamarellos-Bourboulis EJ, Netea MG, Rovina N et al. Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure. *Cell Host Microbe* 2020; 27(6):992-1000.
5. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. *J Infect* 2020; 80(6):607-13.
6. Theoharides TC, Antonopoulou S, Demopoulos CA. Coronavirus 2019, microthromboses, and platelet activating factor. *Clin Ther* 2020; doi: 10.1016/j.clinthera.2020.08.006. Online ahead of print.
7. Gotzinger F, Santiago-Garcia B, Noguera-Julian A, et al. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. *Lancet Child Adolesc Health* 2020; 4(9):653-61.
8. She J, Liu L, Liu W. COVID-19 epidemic: Disease characteristics in children. *J Med Virol* 2020; 92(7):747-54.
9. Castagnoli R, Votto M, Licari A, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review. *JAMA Pediatr* 2020; doi: 10.1001/jamapediatrics.2020.1467. Online ahead of print.
10. Greene AG, Saleh M, Roseman E, Sinert R. Toxic shock-like syndrome and COVID-19: A case report of multisystem inflammatory syndrome in children (MIS-C). *Am J Emerg Med* 2020; S0735-6757(20):30492-97.
11. Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem inflammatory syndrome in U.S. children and adolescents. *N Engl J Med* 2020; 383(4):334-46.
12. Gupta A, Madhavan MV, Sehgal K, et al. Extrapulmonary manifestations of COVID-19. *Nat Med* 2020; 26(7):1017-32.
13. Helms J, Kremer S, Merdji H et al. Neurologic Features in Severe SARS-CoV-2 Infection. *N Engl J Med* 2020; 382(23):2268-70.
14. Najjar S, Najjar A, Chong DJ et al. Central nervous system complications associated with SARS-CoV-2

- infection: integrative concepts of pathophysiology and case reports. *J Neuroinflammation* 2020; 17(1):231.
15. Theoharides TC. Stress, inflammation, and autoimmunity: The 3 modern erinyes. *Clin Ther* 2020; 42(5):742-44.
 16. Kempuraj D, Selvakumar GP, Ahmed ME et al. COVID-19, mast cells, cytokine storm, psychological stress, and neuroinflammation. *Neuroscientist* 2020; 26(5-6):402-14.
 17. Theoharides TC, Valent P, Akin C. Mast cells, mastocytosis, and related disorders. *N Engl J Med* 2015; 373(2):163-72.
 18. Akin C, Valent P, Metcalfe DD. Mast cell activation syndrome: Proposed diagnostic criteria. *J Allergy Clin Immunol* 2010; 126(6):1099-104.
 19. Theoharides TC. Effect of psychological stress on mast cells. *Annals Allergy, Asthma, Immunology* 125[4], 388-92.
 20. Theoharides TC, Tsilioni I, Ren H. Recent advances in our understanding of mast cell activation - or should it be mast cell mediator disorders? *Expert Rev Clin Immunol* 2019; 15(6):639-56.
 21. Kritas SK, Ronconi G, Caraffa A, Gallenga CE, Ross R, Conti P. Mast cells contribute to coronavirus-induced inflammation: new anti-inflammatory strategy. *J Biol Regul Homeost Agents* 2020; 34(1):9-14.
 22. Olivera A, Beaven MA, Metcalfe DD. Mast cells signal their importance in health and disease. *J Allergy Clin Immunol* 2018; 142(2):381-93.
 23. Marshall JS, Portales-Cervantes L, Leong E. Mast cell responses to viruses and pathogen products. *Int J Mol Sci* 2019; 20(17):4241.
 24. Theoharides TC. COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin. *Biofactors* 2020; 46(3):306-308.
 25. Mukai K, Tsai M, Saito H, Galli SJ. Mast cells as sources of cytokines, chemokines, and growth factors. *Immunol Rev* 2018; 282(1):121-50.
 26. Gallenga CE, Pandolfi F, Caraffa A et al. Interleukin-1 family cytokines and mast cells: activation and inhibition. *J Biol Regul Homeost Agents* 2019; 33(1):1-6.
 27. Kandere-Grzybowska K, Letourneau R, Kempuraj D et al. IL-1 induces vesicular secretion of IL-6 without degranulation from human mast cells. *J Immunol* 2003; 171(9):4830-36.
 28. Taracanova A, Tsilioni I, Conti P, Norwitz ER, Leeman SE, Theoharides TC. Substance P and IL-33 administered together stimulate a marked secretion of IL-1beta from human mast cells, inhibited by methoxyluteolin. *Proc Natl Acad Sci U S A* 2018; 115(40):E9381-E9390.
 29. Redegeld FA, Yu Y, Kumari S, Charles N, Blank U. Non-IgE mediated mast cell activation. *Immunol Rev* 2018; 282(1):87-113.
 30. McNeil BD, Pundir P, Meeker S, et al. Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. *Nature* 2015; 519(7542):237-41.
 31. Theoharides TC. Neuroendocrinology of mast cells: Challenges and controversies. *Exp Dermatol* 2017; 26(9):751-59.
 32. Pan W, Stone KP, Hsuchou H, Manda VK, Zhang Y, Kastin AJ. Cytokine signaling modulates blood-brain barrier function. *Curr Pharm Des* 2011; 17(33):3729-40.
 33. Theoharides TC, Konstantinidou A. Corticotropin-releasing hormone and the blood-brain-barrier. *Front Biosci* 2007; 12:1615-28.
 34. Conti P, Ronconi G, Caraffa A et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. *J Biol Regul Homeost Agents* 2020; 34(2):327-31.
 35. Theoharides TC. Luteolin containing dietary supplements: all that glitters is not gold. *Biofactors*. 2020, In press.